All News

acr_session2.jpeg

EULAR 2022 – Day 2 Report

Jack Cush, MD

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.

Read Article
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Read Article
cardiac2.jpg (keep)

Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease

Jack Cush, MD

The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.

Read Article
dementia,brain

Is Gout Protective Against Dementia?

MedPage Today

People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

Jack Cush, MD

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Read Article
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

David Liew drdavidliew ( View Tweet)

#EULAR2022 POS0278: Proof of concept US study: 💎CPP crystals do NOT generate posterior shadowing 💎MSU and hydroxyapatite did have shadowing, proportional to concentration of crystals @Rheumnow @MymaAlbaydaMD @USSONAR_Rh

Eric Dein ericdeinmd ( View Tweet)

Dr Puja Khanna. Transdermal sodium bicarbonate for gout flare. WHAT!? It works as well! Double-blind RCT. All got colchicine also. Response rate 95% vs 79%. Resolution in 24 vs 72 hrs. Rescue meds 6% vs 20%. No adverse events! @RheumNow #EULAR2022 OP0170 https://t.co/INd4tMFVlV https://t.co/EyVjFLF72z

Links:

Richard Conway RichardPAConway ( View Tweet)
Farshad et al. 17% of admissions on long-term allopurinol had it held. Reasons - acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. @RheumNow #EULAR2022 OP0169 https://t.co/ADOomiOrRi https://t.co/nxAAOMWsJB

Links:

Richard Conway RichardPAConway ( View Tweet)
Botson et al. 152 patient RCT. MTX combo with pegloticase (to decrease antidrug abs). 6-month response (sUA<6 mg/dL) 71% vs 39%. Infusion reactions 3% vs 31%. @RheumNow #EULAR2022 OP0171 https://t.co/N29kYT3xkR https://t.co/Z4dUMD4Tt3

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on https://t.co/V10S4oVFsv. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus? https://t.co/iaMQZtzdLm https://t.co/Zu9VwKoCAc

Links:

Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation... https://t.co/u86Vd8bFGr #MedEdTwitter https://t.co/IpKqPoWM9R

Links:

Dr. John Cush RheumNow ( View Tweet)
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increaseing negative associations w/ NAFLD severity (mild OR 0.392; Mod: 0.379; Severe 0.148). NAFLD negatively assoc w/ CKD risk in gout https://t.co/5fuIiO1LwM https://t.co/Jp8CjWkn5m

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 100 pts w/ gouty arthritis, 51% had hypertension, nearly half insufficiently controlled. Undiagnosed HTN was seen in 18%. Gouty pts w/ HTN frequently (92%) had serum uric acid levels above the target https://t.co/jc0UGyrK2B https://t.co/kDD2KfQd3K

Links:

Dr. John Cush RheumNow ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Cool NEJM Case of Spinal Gout in 82-yr-old woman with 3-wk hx of severe LBP, rigors, anorexia, incomplete urination. Hx of PsA, CKD, CHF treated w/ Humira, HCQ, diuretics. Imaging tophi in spine, responded to steroids and allopurinol. https://t.co/JgH2bPsDeu https://t.co/RAPNxohe55

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD. https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14); but lower in Latinos (HR 0.78) compared to whites. https://t.co/lQiSx0ExAM https://t.co/bVx41mbquW

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×